Hyderabad News Desk

DelveInsight’s, “Glaucoma Pipeline Insight 2023” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Glaucoma pipeline landscape. It covers the Glaucoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glaucoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Glaucoma Pipeline Report

• DelveInsight’s Glaucoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Glaucoma treatment.
• The leading companies working in the Glaucoma Market include Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, TearClear, Laboratoires Thea, EMS, Peregrine Ophthalmic, Betaliq, Inc., Ocuphire Pharma, Inc., HK inno.N, VivaVision Biotech, Qlaris Bio, and others.
• Promising Glaucoma Pipeline Therapies in the various stages of development include rhNGF, Aflibercept (Eylea, BAY 86-5321), and others.
• September 2023: AbbVie announced a study of Phase 3 clinical trials for XEN45 (Glaucoma Gel Stent). All participants will receive XEN45 implanted using the ab externo approach on Day 1 and will be followed for 12 months. Participants will attend regular visits during the study at a hospital or clinic. The safety and effect of the gel stent on your glaucoma will be checked by medical assessments and eye examinations.
• July 2023: Santen Pharmaceuticals Co. Ltd announced a study of phase 3 clinical trials for A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL. The objective of this study is to investigate whether the IOP (intraocular pressure) -lowering effect of DE-111A (preservative-free fixed dose combination of 0.0015% tafluprost and 0.5% timolol eye drops, administered one drop a time, once daily for 3 months) is superior to the monotherapy of tafluprost 0.0015% eye drops administered one drop a time, once daily for 3 months) in subjects with open-angle glaucoma or ocular hypertension in China as well as comparison of safety.

Request a sample and discover the recent advances in Glaucoma Treatment Drugs @ Glaucoma Pipeline Report

In the Glaucoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glaucoma Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Glaucoma Overview

Glaucoma is a group of eye conditions that damage the optic nerve. The optic nerve sends visual information from eye to the brain and is vital for good vision. Damage to the optic nerve is often related to high pressure in your eye. But glaucoma can happen even with normal eye pressure. Glaucoma can occur at any age but is more common in older adults. It is one of the leading causes of blindness for people over the age of 60.

Find out more about Glaucoma Therapeutics Assessment @ Glaucoma Preclinical and Discovery Stage Products

Glaucoma Emerging Drugs Profile

• GmbH NCX 470: Nicox Ophthalmics
• DE-126: Santen Pharmaceuticals
• POLAT 001: Peregrine Ophthalmic
• BTQ-1902: Betaliq, Inc.
• ST266: Noveome Biotherapeutics

Glaucoma Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the Glaucoma therapies. The Glaucoma companies which have their Glaucoma Disease drug candidates in the most advanced stage, i.e. phase III include, Nicox Ophthalmics.

Learn more about the emerging Glaucoma Pipeline Therapies @ Glaucoma Clinical Trials Assessment

Scope of the Glaucoma Pipeline Report

• Coverage- Global
• Glaucoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Glaucoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Glaucoma Companies- Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, TearClear, Laboratoires Thea, EMS, Peregrine Ophthalmic, Betaliq, Inc., Ocuphire Pharma, Inc., HK inno.N, VivaVision Biotech, Qlaris Bio, and others.
• Glaucoma Pipeline Therapies- rhNGF, Aflibercept (Eylea, BAY 86-5321), and others.

Dive deep into rich insights for new drugs for Glaucoma Treatment, Visit @ Glaucoma Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction
2. Executive Summary
3. Glaucoma Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Glaucoma Disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. NCX 470: Nicox Ophthalmics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. POLAT 001: Peregrine Ophthalmic
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ST266: Noveome Biotherapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. RTC-1119: Ripple Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Glaucoma Disease Key Companies
21. Glaucoma Disease Key Products
22. Glaucoma Disease- Unmet Needs
23. Glaucoma Disease- Market Drivers and Barriers
24. Glaucoma Disease- Future Perspectives and Conclusion
25. Glaucoma Disease Analyst Views
26. Glaucoma Disease Key Companies
27. Appendix

For further information on the Glaucoma Pipeline therapeutics, reach out to Glaucoma Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking